APA (7th ed.) Citation

Yang, M., Huang, C., Chang, D., Hu, F., Huang, S., Huang, P., . . . Lu, Y. (2024). Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis. Cancer Medicine, 13(14), 1. https://doi.org/10.1002/cam4.70005

Chicago Style (17th ed.) Citation

Yang, Ming‐Han, et al. "Concurrent Epirubicin and Trastuzumab Use Increases Complete Pathological Response Rate Without Additional Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2‐positive Early Breast Cancer: A Meta‐regression Analysis." Cancer Medicine 13, no. 14 (2024): 1. https://doi.org/10.1002/cam4.70005.

MLA (9th ed.) Citation

Yang, Ming‐Han, et al. "Concurrent Epirubicin and Trastuzumab Use Increases Complete Pathological Response Rate Without Additional Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2‐positive Early Breast Cancer: A Meta‐regression Analysis." Cancer Medicine, vol. 13, no. 14, 2024, p. 1, https://doi.org/10.1002/cam4.70005.